Exchange: NASDAQ·Updated 07:59 PM EDT
News
all
press releases
Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?
Key PointsEli Lilly leads the GLP-1 market and could remain on top thanks to a deep pipeline...
Nasdaq News: Markets
More News
Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished
Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished...
Yahoo! Finance: News
Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?
NVO heads into Q2 earnings under pressure as slowing injectable GLP-1 momentum, pricing headwinds and fierce competition cloud the near-term outlook.
Zacks
VKTX Launches $500M Shelf After Full Enrollment Of Phase 3 Obesity Drug Study – Retail Bets On ‘Exceptionally Great Data’
Viking Therapeutics said the proceeds would be used to support the continued development and commercialization of its lead obesity drug VK2735.
Stocktwits
VKTX Q2 Earnings Beat Estimates Despite Surge in R&D Costs
Viking Therapeutics beats second-quarter loss estimates as it advances late-stage obesity studies despite sharply higher R&D spending tied to its expanding pipeline.
Zacks
VKTX Stock Lags GLP-1 Peers In July — But Viking CEO Says Its Obesity Drug Could Offer What Rivals Can’t
Viking expects oral VK2735 Phase 3 studies to begin in Q4 and believes the pill could become the first oral dual GLP-1 agonist to reach the market.
Stocktwits
VKTX Stock Steady After-Hours On Positive Obesity Drug Pipeline Progress
Viking has no approved drug products, and in the pre-revenue phase, investor attention centers almost entirely on clinical progress.
Stocktwits
Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update PR Newswire SAN DIEGO, July 29, 2026 Conference call scheduled for 4:30 p.m. ET today-- Phase 3 VANQUISH 1...
PR Newswire
How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q2 Results?
Novo Nordisk's Q2 results are set to spotlight Ozempic and Wegovy sales as oral launches and label expansions drive growth amid mounting competitive pressure.
Zacks
Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates?
Biotech earnings take center stage as Viking, Biogen, Bristol Myers, Regeneron and AbbVie prepare to report Q2 2026 results.
Zacks

Advertisement|Remove ads.